Amgen
 
2Q Revenues: $4.5 billion (+13%)

2Q Earnings: $1.3 billion (+8%)

YTD Revenues: $8.5 billion (+11%)

YTD Earnings: $2.5 billion (+7%)

Comments: Neulasta and Neupogen sales were up 2% to $1.3 billion in the quarter. Enbrel sales rose 11% to $1.1 billion. Aranesp sales dropped 8% to $536 million, due to a decline in demand. Epogen sales decreased 3% to $525 million. Sensipar/Mimpara sales were up 17% to $232 million. Vectibix sales were up 11% to $90 million, and Nplate sales were up 15% to $86 million. Other revenues increased to $277 million in the quarter, versus $66 million in 2Q11, driven by changes to the company's motesanib collaboration with Takeda.